Inozyme Pharma To Present Recently Announced Data From Phase 1/2 Trials Of INZ-701 In Adults With ENPP1 Deficiency And ABCC6 Deficiency (PXE) At Upcom...

BOSTON, May 23, 2024 (GLOBE NEWSWIRE) --

Related Keywords

United States ,France ,Boston ,Massachusetts ,America ,Pseudoxanthoma Elasticum ,Stefan Riley ,Yves Sabbagh ,Matt Pera ,Inozyme Pharma ,Kurt Gunter ,Endocrine Society Annual Meeting ,Exchange Commission ,Facebook ,European Calcified Tissue Society Congress ,Corporate Communications ,Company Or Inozyme ,Nasdaq ,Boston Convention Exhibition Center ,Inozyme Pharma Inc ,Clinical Public Health ,Mineral Metabolism Biomarkers ,Clinical Outcomes ,Concurrent Oral Presentations ,Rare Bone ,Senior Vice President ,Chief Scientific ,Exploratory Efficacy ,Label Study ,Concurrent Oral Poster Presentations ,Endocrine Society ,Annual Meeting ,Oral Abstract ,Boston Convention ,Exhibition Center ,Chief Medical ,Trial Design ,North America ,Private Securities Litigation Reform Act ,Annual Report ,Senior Director ,